Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
Marketing Status Prescription; Discontinued
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atrial flutter02.03.03.0030.000808%
Atrial tachycardia02.03.03.0040.000202%
Atrioventricular block complete02.03.01.0030.000202%
Atrioventricular block first degree02.03.01.0040.001010%
Atrophic vulvovaginitis21.02.01.0030.001819%Not Available
Atrophy08.03.04.0010.000909%Not Available
Autoimmune hepatitis10.04.09.001; 09.01.07.0190.000202%Not Available
Azotaemia20.01.01.0010.000303%Not Available
Back disorder15.03.01.0140.001414%Not Available
Back pain15.03.04.0050.023036%
Bacterial disease carrier11.07.03.0010.000303%Not Available
Barrett's oesophagus07.11.03.0020.000909%Not Available
Bartholin's cyst21.08.03.001; 16.04.04.0030.000303%Not Available
Basal cell carcinoma23.08.02.001; 16.03.02.0010.003334%Not Available
Basedow's disease06.09.04.003; 05.02.02.003; 10.04.08.0040.000303%Not Available
Benign breast neoplasm21.05.01.009; 16.14.01.0050.000707%Not Available
Benign neoplasm of skin23.10.01.006; 16.26.01.0060.000505%Not Available
Benign prostatic hyperplasia21.04.02.0010.000808%Not Available
Bile duct stone09.02.02.0030.000303%Not Available
Biopsy breast13.20.02.0040.001010%Not Available
Bladder cancer20.03.04.001; 16.08.01.001--Not Available
Bladder dilatation20.03.01.0070.000202%Not Available
Bladder discomfort20.02.02.0190.000202%Not Available
Bladder neoplasm20.03.04.002; 16.08.03.0020.000404%Not Available
Bleeding time prolonged13.01.02.0020.000202%Not Available
Blepharitis23.03.04.012; 06.04.04.0010.000808%Not Available
Blindness17.17.01.003; 06.02.02.0010.001010%Not Available
Blindness unilateral17.17.01.016; 06.02.02.0090.000404%Not Available
Blister23.03.01.001; 12.01.06.0020.001516%Not Available
Blood albumin decreased13.09.01.0010.000505%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 49 Pages